Timing of androgen-deprivation therapy for prostate cancer: still a long way to go Reply

被引：1

作者：

Duchesne, Gillian M. ^{[1
,2
]}

机构：

[1] Univ Melbourne, Peter Mac Canc Ctr, Melbourne, Vic 3000, Australia

[2] Monash Univ, Peter Mac Canc Ctr, Melbourne, Vic 3000, Australia

来源：

LANCET ONCOLOGY | 2016年 / 17卷 / 08期

关键词：

D O I：

10.1016/S1470-2045(16)30282-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E313 / E314

页数：3

共 2 条

[1] Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database [J].

Antonarakis, Emmanuel S. ;

Chen, Yongmei ;

Elsamanoudi, Sally I. ;

Brassell, Stephen A. ;

Da Rocha, Mario V. ;

Eisenberger, Mario A. ;

McLeod, David G. .

BJU INTERNATIONAL, 2011, 108 (03) :378-385

[2] Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial [J].

Duchesne, Gillian M. ;

Woo, Henry H. ;

Bassett, Julie K. ;

Bowe, Steven J. ;

D'Este, Catherine ;

Frydenberg, Mark ;

King, Madeleine ;

Ledwich, Leo ;

Loblaw, Andrew ;

Malone, Shawn ;

Millar, Jeremy ;

Milne, Roger ;

Smith, Rosemary G. ;

Spry, Nigel ;

Stockler, Martin ;

Syme, Rodney A. ;

Tai, Keen Hun ;

Turner, Sandra .

LANCET ONCOLOGY, 2016, 17 (06) :727-737

← 1 →